Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells

Cell Biochemistry and Function

Volumn 30, Issue 1, 2012, Pages 11-17

  Song, Bao ^a   Song, Wei Guo ^c   Li, Zeng Jun ^a   Xu, Zhong Fa ^a   Wang, Xing Wu ^a   Wang, Chuan Xi ^b   Liu, Jie ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c Shandong Institute of Traditional Chinese Medicine   (China)

Author keywords

Apoptosis; Gastric cancer; High mobility group box1 (HMGB1); Invasion; Proliferation; RNA interference

Indexed keywords

CASPASE 3; CYCLIN D1; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; HMGB1 PROTEIN, HUMAN; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CANCER INVASION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH CANCER; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; GENETIC VECTORS; HMGB1 PROTEIN; HUMANS; LENTIVIRUS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 84855334252     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1811     Document Type: Article

References (29)

1. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7: 315-321. doi:10.1177/09680519010070041401.
2. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251. doi:10.1126/science.285.5425.248.
3. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360. doi:10.1038/35012626.
4. Terrando N, Monaco C, Ma D, et al. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci USA 2010; 107: 20518-20522. doi:10.1073/pnas.1014557107.
5. Gdynia G, Keith M, Kopitz J, et al. Danger signalling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res 2010; 70: 8558-8568. doi:10.1158/0008-5472.CAN-10-0204.
6. Tang D, Kang R, Zeh HJ, 3rd, Lotze MT. High-mobility group box1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140. doi:10.1016/j.bbagrm.2009.11.014.
7. Zhang M, Swanson PC. HMGB1/2 can target DNA for illegitimate cleavage by the RAG1/2 complex. BMC Mol Biol 2009; 10: 24. doi:10.1186/1471-2199-10-24.
8. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007; 28: 1957-1967. doi:10.1111/j.1745-7254.2007.00669.x.
9. Kuniyasu H, Yano S, Sasaki T, et al. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005; 166: 751-760. PMID: 15743787.
10. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-727. doi:10.1002/ijc.11016.
11. Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005; 64: 92-100. doi:10.1002/pros.20219.
12. Kawahara N, Tanaka T, Yokomizo A, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996; 56: 5330-5333. PMID: 8968078.
13. Liu PL, Tsai JR, Hwang JJ, et al. High-mobility group box1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010; 43: 530-538. doi:10.1165/rcmb.2009-0269OC.
14. Akaike H, Kono K, Sugai H, et al. Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007; 27: 449-457. PMID: 17352266.
15. Xiang YY, Wang DY, Tanaka M, et al. Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. Int J Cancer 1997; 74: 1-6. doi:10.1002/(SICI)1097-0215(19970220).
16. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-170. doi:10.1002/path.1031.
17. Chung HW, Lee SG, Kim H, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38. doi:10.1186/1479-5876-7-38.
18. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991-2998. doi:10.1128/MCB.23.8.2991-2998.2003.
19. Park JS, Arcaroli J, Yum HK, et al. Activation of gene expression in human neutrophils by high mobility group box1 protein. Am J Physiol Cell Physiol 2003; 284: C870-879. doi:10.1152/ajpcell.00322.2002.
20. Palumbo R, Galvez BG, Pusterla T, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 2007; 179: 33-40. doi:10.1083/jcb.200704015.
21. Ren M, Zhong X, Ma CY, et al. Insulin-like growth factor-1 promotes cell cycle progression via upregulation of cyclin D1 expression through the phosphatidylinositol 3-kinase/nuclear factor-kappaB signaling pathway in FRTL thyroid cells. Acta Pharmacol Sin 2009; 30: 113-119. doi:10.1038/aps.2008.8.
22. Ma J, Liu C, Chen Y, et al. Cellular and molecular mechanisms of the Ganoderma applanatum extracts induces apoptosis on SGC-7901 gastric cancer cells. Cell Biochem Funct 2011; 29(3): 175-182. doi:10.1002/cbf.1735.
23. Virag P, Brie I, Fischer-Fodor E, et al. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance. Cell Biochem Funct 2011 Apr 13. DOI: 10.1002/cbf.1754.
24. Wang Z, Zhou J, Fan J, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs 2009; 18: 1595-1604. doi:10.1517/13543780903292626.
25. Brezniceanu ML, Volp K, Bosser S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003; 17: 1295-1297. doi:10.1096/fj.02-0621fje.
26. Krynetskaia N, Xie H, Vucetic S, et al. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol 2008; 73: 260-269. doi:10.1124/mol.107.041764.
27. Tang D, Kang R, Cheh CW, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310. doi:10.1038/onc.2010.261.
28. Sampieri CL, de la Peña S, Ochoa-Lara M, et al. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol 2010; 16: 1500-1505. doi:10.3748/wjg.v16.i12.1500.
29. Takada M, Hirata K, Ajiki T, et al. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004; 51: 928-930. PMID: 15239215.